CD19 and acute myeloid leukemia: BiKEs and TriKEs designed to engage tumor antigens (e.g., CD19, CD20 for B cell NHL; CD33 and CD123 for AML; CD30 for HL), and CD16 receptor facilitate NK cell immunological synapse formation.